Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsSector news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

10/08/2012 | 01:44am US/Eastern

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.


- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
React to this article
Latest news on SANOFI
10/01 Study Results from University Hospital Provide New Insights into Proinsulin (..
10/01 SANOFI : Findings from Sanofi Pasteur Provides New Data about Clostridium Infect..
10/01 SANOFI : Researchers from Sanofi Pasteur Discuss Findings in Vaccines (Optimizat..
10/01 SANOFI : New Flavivirus Findings Reported from Sanofi Pasteur (Preparation of pu..
10/01 SANOFI : Announces Launch of Authorized Generic Version of Arava® (Leflunomide) ..
10/01 REGENERON PHARMACEUTICALS : Assigned Ornamental Design Patent
10/01 SANOFI : Alnylam and Genzyme Announce that Genzyme Opts into ALN-AT3 Hemophilia ..
10/01 SANOFI : Genzyme Opts into Alnylam's ALN-AT3 Hemophilia Program for Development ..
10/01 ZEALAND PHARMA AKTIESELSKABET : announces total number of shares and voting righ..
09/30 SANOFI : Reaches Patent Settlement on Lantus SoloSTAR
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials